Retatrutide

Retatrutide (development code LY3437943) is a single synthetic peptide, conjugated to a fatty-diacid chain, that activates three hormone receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCG) receptor. The published literature describes it as the first "triple agonist" of this kind to reach phase 2 clinical data in both obesity and type 2 diabetes.

What distinguishes it from earlier incretin therapies is the third target. Semaglutide acts on the GLP-1 receptor alone; tirzepatide acts on two, GIP and GLP-1. Retatrutide adds glucagon-receptor activity, and researchers have proposed that this addition is the reason for some of the effects observed in trials. Its reported half-life of roughly six days is what allows the once-weekly dosing schedule used in studies.

Cell-culture work characterized how strongly retatrutide engages each of its three receptors. Relative to the body's own signaling molecules, published potency data describe it as notably more active at the GIP receptor and somewhat less active at the glucagon and GLP-1 receptors — a deliberately unbalanced profile that researchers have framed as central to how the compound behaves.

The proposed rationale in the literature is that GLP-1 and GIP activity drive reduced food intake and improved glucose handling, while the added glucagon-receptor activity is associated with increased energy expenditure and, in trial substudies, with pronounced reductions in liver fat. Reviews note that the ratio of glucagon to GLP-1 activity is considered an important determinant of both the efficacy and the safety profile of this class.

The evidence has moved quickly. Early phase 2 work — a 48-week obesity trial in the New England Journal of Medicine and a type-2-diabetes trial in The Lancet — reported mean weight reductions up to roughly 24% and meaningful glycemic improvement. A Nature Medicine phase 2a substudy reported large relative reductions in liver fat versus placebo.

By late 2025, the phase 3 TRIUMPH program began reading out. TRIUMPH-4, a 68-week trial in adults with obesity and knee osteoarthritis, reported average weight reduction up to 28.7% at the highest dose alongside substantial pain-score improvement, and the phase 3 TRANSCEND-T2D-1 diabetes trial reported HbA1c reductions up to roughly 2%. Across trials the dominant adverse events remained gastrointestinal and dose-escalation-related, with a dose-dependent heart-rate increase noted. A dedicated cardiovascular-outcomes trial enrolling thousands is still running — the readout regulators need before broad labeling.

The following summarizes what published studies have observed under controlled clinical conditions. It is reported for transparency and education only. It is not a description of what any individual should expect, and nothing here endorses or supports use outside an authorized clinical trial. Retatrutide is investigational; it is not approved for human or veterinary use, and its full safety profile is not yet established.

Observed effects in human trials. Across phase 2 and phase 3 studies, participants under medical supervision showed dose-dependent reductions in body weight (reported up to roughly 24–29% at the highest doses over 48–68 weeks), improvements in blood glucose and HbA1c, reductions in liver fat, and improvements in some cardiovascular risk markers such as blood pressure and non-HDL cholesterol.

Documented adverse events and risks. The same trials consistently reported side effects. Gastrointestinal events — nausea, vomiting, diarrhea, constipation — were the most common and occurred most during dose escalation. A dose-dependent increase in heart rate was observed across studies. Because glucagon-receptor activation can affect glucose regulation and energy metabolism, this class is monitored closely in supervised settings. Critically, the dedicated cardiovascular-outcomes trial is still ongoing: the long-term safety picture that regulators require before approval does not yet exist.

Why supervision matters. Every one of these findings comes from trials with medical screening, gradual dose titration, monitoring, and defined stopping rules. The published record describes outcomes within that controlled context — not outcomes for someone self-administering an unapproved compound without those safeguards, where the risk profile is unknown and unmonitored.

• 01Jastreboff AM, et al. — Triple–Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine, 2023. PMID 37366315Source →
• 02Rosenstock J, et al. — Retatrutide for people with type 2 diabetes: a phase 2 trial. The Lancet, 2023. PMID 37385280Source →
• 03Sanyal AJ, et al. — Retatrutide for MASLD: a randomized phase 2a trial. Nature Medicine, 2024. PMID 38858523Source →

These are three of 47 indexed papers on this compound. The complete citation ledger — every trial, meta-analysis, and mechanistic study, tagged and searchable — is held in the deep-dive below.